Investor Information

Aisa is currently launching a Series A financing round in the amount of $50M to complete development of AISA-021 for the Treatment of Raynaud’s Phenomenon in patients with Systemic Sclerosis and submit an NDA to the US FDA. The company has until this point been financed with seed and angel investments. For information or to obtain a copy of financing documents and additional information please email us at ir@aisapharma.com.